Shots:

• Shape is eligible to receive $3B+ including initial payment- development- regulatory- and sales milestone along with royalties on sales of therapies resulting from the collaboration
• The collaboration will utilize Shape’s RNA editing platform i.e.- RNAfix and AAVid for next-generation tissue-specific AAVs to develop gene therapy for AD- PD & rare diseases
• Shape to conduct preclinical research to identify & deliver development candidates discovered by RNAfix and AAVid AI-powered platforms. Roche will lead the development & global commercialization of any potential products that emerge from the collaboration

 Ref: Globe Newswire | Image: Roche